glulisinepotassium acid phosphate increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin lispropotassium acid phosphate increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin NPHpotassium acid phosphate increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin regular humanpotassium acid phosphate increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.iodinated glyceroliodinated glycerol increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.iodineiodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.metforminpotassium acid phosphate increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.miglitolpotassium acid phosphate increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.nateglinidepotassium acid phosphate increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.pioglitazonepotassium acid phosphate increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.repaglinidepotassium acid phosphate increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.rosiglitazonepotassium acid phosphate increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.saxagliptinpotassium acid phosphate increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.sitagliptinpotassium acid phosphate increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.tolazamidepotassium acid phosphate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.tolbutamidepotassium acid phosphate increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.vildagliptinpotassium acid phosphate increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.acarboseMinor (1)potassium acid phosphate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.acebutololMonitor Closely (1)acebutolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.aceclofenacMonitor Closely (1)aceclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.acemetacinMonitor Closely (1)acemetacin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.albuterolMonitor Closely (1)potassium acid phosphate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.amilorideSerious - Use Alternative (1)amiloride and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.amphotericin B deoxycholateMinor (1)amphotericin B deoxycholate decreases levels of potassium acid phosphate by increasing renal clearance. Minor/Significance Unknown.arformoterolMonitor Closely (1)potassium acid phosphate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.aspirinMonitor Closely (1)aspirin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.aspirin rectalMonitor Closely (1)aspirin rectal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.aspirin/citric acid/sodium bicarbonateMonitor Closely (1)aspirin/citric acid/sodium bicarbonate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.atenololMonitor Closely (1)atenolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.benazeprilMonitor Closely (2)benazepril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia. potassium acid phosphate and benazepril both increase serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ACE inhibitors; the effect may be the result of aldosterone suppression in patients receiving ACE inhibitorsbendroflumethiazideMonitor Closely (1)potassium acid phosphate increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.betaxololMonitor Closely (1)betaxolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.bisacodylMinor (1)bisacodyl decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.bisacodyl rectalMinor (1)bisacodyl rectal decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.bisoprololMonitor Closely (1)bisoprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.bumetanideMonitor Closely (1)potassium acid phosphate increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.cadexomer iodineMinor (1)cadexomer iodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.canagliflozinMonitor Closely (1)potassium acid phosphate and canagliflozin both increase serum potassium. Modify Therapy/Monitor Closely.candesartanMonitor Closely (1)candesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.captoprilMonitor Closely (1)captopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.carbenoxoloneMonitor Closely (1)potassium acid phosphate increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.carvedilolMonitor Closely (1)carvedilol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.celecoxibMonitor Closely (1)celecoxib and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.celiprololMonitor Closely (1)celiprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.chlorothiazideMonitor Closely (1)potassium acid phosphate increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.chlorpropamideMinor (1)potassium acid phosphate increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.chlorthalidoneMonitor Closely (1)potassium acid phosphate increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.choline magnesium trisalicylateMonitor Closely (1)choline magnesium trisalicylate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.cyclopenthiazideMonitor Closely (1)potassium acid phosphate increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.dextroamphetamine transdermalMonitor Closely (1)potassium acid phosphate will decrease the level or effect of dextroamphetamine transdermal by Other (see comment). Modify Therapy/Monitor Closely. Urinary acidifying agents can lower blood levels and efficacy of amphetamines. Increase dose of dextroamphetamine transdermal based on clinical response.diclofenacMonitor Closely (1)diclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.diflunisalMonitor Closely (1)diflunisal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.digoxinMonitor Closely (1)potassium acid phosphate and digoxin both increase serum potassium. Modify Therapy/Monitor Closely.disopyramideMonitor Closely (1)potassium acid phosphate increases effects of disopyramide by pharmacodynamic synergism. Use Caution/Monitor. Additive cardiovascular depression.dobutamineMonitor Closely (1)potassium acid phosphate increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.dopexamineMonitor Closely (1)potassium acid phosphate increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.drospirenoneSerious - Use Alternative (1)drospirenone and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.enalaprilMonitor Closely (1)enalapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.ephedrineMonitor Closely (1)potassium acid phosphate increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.epinephrineMonitor Closely (1)potassium acid phosphate increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.epinephrine racemicMonitor Closely (1)potassium acid phosphate increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.eplerenoneSerious - Use Alternative (1)potassium acid phosphate, eplerenone. Mechanism: pharmacodynamic synergism. Contraindicated. Hyperkalemia.eprosartanMonitor Closely (1)eprosartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.erdafitinibSerious - Use Alternative (1)potassium acid phosphate, erdafitinib. Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid coadministration during initial dosing adjustment period (ie, first 21 days). Increases in serum phosphate levels are a pharmacodynamic effect of FGFR inhibition. Serum phosphate binders may obscure decisions regarding initial dosage increase.esmololMonitor Closely (1)esmolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.ethacrynic acidMonitor Closely (1)potassium acid phosphate increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.etodolacMonitor Closely (1)etodolac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.fenoprofenMonitor Closely (1)fenoprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.finerenoneMonitor Closely (1)potassium acid phosphate and finerenone both increase serum potassium. Modify Therapy/Monitor Closely. Finerenone dose adjustment based on current serum potassium concentration. Monitor serum potassium and adjust finerenone dose as described in the prescribing information as necessary.flurbiprofenMonitor Closely (1)flurbiprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.formoterolMonitor Closely (1)potassium acid phosphate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.fosinoprilMonitor Closely (1)fosinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.furosemideMonitor Closely (1)potassium acid phosphate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.gentamicinMonitor Closely (1)potassium acid phosphate increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.glimepirideMinor (1)potassium acid phosphate increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.glipizideMinor (1)potassium acid phosphate increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.glyburideMinor (1)potassium acid phosphate increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.hydrochlorothiazideMonitor Closely (1)potassium acid phosphate increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.ibuprofenMonitor Closely (1)ibuprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.ibuprofen IVMonitor Closely (1)ibuprofen IV and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.imidaprilMonitor Closely (1)imidapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.indapamideMonitor Closely (1)potassium acid phosphate increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.indomethacinMonitor Closely (1)indomethacin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.insulin aspartMinor (1)potassium acid phosphate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin detemirMinor (1)potassium acid phosphate increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin glargineMinor (1)potassium acid phosphate increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin glulisineMinor (1)potassium acid phosphate increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin lisproMinor (1)potassium acid phosphate increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin NPHMinor (1)potassium acid phosphate increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.insulin regular humanMinor (1)potassium acid phosphate increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.iodinated glycerolMinor (1)iodinated glycerol increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.iodineMinor (1)iodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.irbesartanMonitor Closely (1)irbesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.isoproterenolMonitor Closely (1)potassium acid phosphate increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.ketoprofenMonitor Closely (1)ketoprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.ketorolacMonitor Closely (1)ketorolac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.ketorolac intranasalMonitor Closely (1)ketorolac intranasal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.labetalolMonitor Closely (1)labetalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.levalbuterolMonitor Closely (1)potassium acid phosphate increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.lisinoprilMonitor Closely (1)lisinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.lornoxicamMonitor Closely (1)lornoxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.losartanMonitor Closely (1)losartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.meclofenamateMonitor Closely (1)meclofenamate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.mefenamic acidMonitor Closely (1)mefenamic acid and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.meloxicamMonitor Closely (1)meloxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.metaproterenolMonitor Closely (1)potassium acid phosphate increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.metforminMinor (1)potassium acid phosphate increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.methyclothiazideMonitor Closely (1)potassium acid phosphate increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely. .metolazoneMonitor Closely (1)potassium acid phosphate increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.metoprololMonitor Closely (1)metoprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.miglitolMinor (1)potassium acid phosphate increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment